The deadly intersection of kidney failure and heart attack has long confounded clinicians — patients with chronic kidney disease face dramatically elevated cardiac mortality, yet the shared molecular machinery driving both conditions has remained opaque. Identifying actionable biological targets at this crossroads could reshape how cardiorenal syndrome is managed in high-risk populations.
This multi-method investigation combined Mendelian randomization, transcriptomic analysis, single-cell sequencing, and in vivo animal experiments to map shared pathogenic terrain between acute myocardial infarction and chronic kidney disease. Mendelian randomization — which uses genetic variants as instruments to infer causality — confirmed CKD as a genuine causal driver of coronary artery disease, not merely a correlate. From a broader gene intersection analysis, 12 genes were found shared across AMI, CKD, and PANoptosis — an inflammatory programmed cell death pathway integrating pyroptosis, apoptosis, and necroptosis. Two genes, SOCS3 and HSPA1A, emerged as top diagnostic candidates, each achieving area-under-the-curve values exceeding 0.85 in independent validation cohorts for AMI. Single-cell sequencing pinpointed their highest expression in monocytes and endothelial cells, implicating innate immune and vascular biology centrally. Crucially, in vivo knockdown of SOCS3 in post-infarction animal models significantly inhibited PANoptosis and preserved cardiac function, anchoring the mechanistic hypothesis experimentally.
The PANoptosis framework is relatively nascent, and this study is among the earlier efforts to apply it to cardiorenal comorbidity — making the findings noteworthy but requiring cautious interpretation. The animal knockdown data are promising yet limited to rodent models; whether therapeutic SOCS3 modulation translates safely to humans, particularly those with compromised renal clearance affecting drug metabolism, remains untested. The JAK-STAT pathway enrichment is biologically coherent — SOCS3 is a canonical JAK-STAT suppressor — lending mechanistic credibility. Overall, this is solid exploratory science that establishes a plausible molecular bridge, but replication in human tissue and clinical cohort validation are necessary before these biomarkers approach translational utility.